



**SymBio Pharmaceuticals Limited**  
San-Ei Building, 5-23-7 Shimbashi, Minato-ku, Tokyo 105-0004, Japan  
Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 <http://www.symbiosis.co.jp/>

February 25, 2008

SymBio Pharmaceuticals Limited

Fuminori Yoshida

Representative Director, President and Chief Executive Officer

## **FDA Accepts TREANDA® New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma**

02/19/2008

FRAZER, Pa., February 19, 2008

Cephalon, Inc. (Nasdaq: CEPH) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's new drug application (NDA) for TREANDA® (bendamustine HCl) for Injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) who have progressed during or following treatment with rituximab or a rituximab-containing regimen. According to the National Cancer Institute, an estimated 30,000 people in the United States were expected to be diagnosed in 2007 with indolent NHL, a serious and slow growing cancer of the lymphatic system that is difficult to treat because patients are prone to relapse after treatment. Cephalon submitted the TREANDA® application for relapsed indolent NHL in December 2007 and a decision from the FDA is expected by October 31, 2008.

"We are pleased that the application for TREANDA® to treat relapsed indolent NHL is on track. With two NDAs for TREANDA® pending review decisions, 2008 is a significant year for this product and bodes well for the future of Cephalon in oncology," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations.

The TREANDA® NDA for relapsed indolent NHL is supported by three studies in patients with NHL, including two single-agent studies and one in combination with rituximab. In these studies, patients treated with TREANDA® had a high rate of response and a manageable and tolerable side effect profile, with adverse events similar to those observed with other chemotherapy agents such as myelosuppression (decrease in blood counts), nausea, and vomiting.

[Company Profile]

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals' focus is on oncology/hematology and autoimmune disease therapies. Established in March 2005 by Fuminori Yoshida, who previously served as both Corporate Vice President of Amgen Inc. and president of Amgen Japan, SymBio Pharmaceuticals' underlying corporate philosophy is "delivering hope to patients in need," and the company aims to address unmet medical needs of patients in Japan by cultivating a mutually beneficial or symbiotic relationship among physicians, scientists, regulatory agencies, and investors. SymBio Pharmaceuticals core philosophy is that profitability and socially responsibility as a pharmaceutical enterprise can go hand in hand, and need not be mutually exclusive.

For further information, please contact:

Osamu Ogawa, Board Director, Senior Corporate Officer, COO

SymBio Pharmaceuticals Limited

Tel: +81(0) 3 5472 1123

E-mail: Please send your inquiry through "INQUIRY" in our homepage

URL: <http://www.symbiosis.co.jp>